Mural Oncology to Host Investor Webcast on October 17

On October 10, 2023 Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans to establish in the fourth quarter of 2023 (Mural Oncology), will hold an investor webcast during which members of Mural Oncology’s designated management team will provide an overview of the company, its pipeline and strategy (Press release, Alkermes, OCT 10, 2023, View Source [SID1234635797]). The event will be webcast live on Tuesday, Oct. 17, 2023, at 11:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited for the opportunities ahead for Mural Oncology and look forward to sharing an in-depth overview of our late-stage clinical asset, nemvaleukin alfa, an investigational immunotherapy, as well our preclinical pipeline candidates," said Dr. Caroline Loew, Chief Executive Officer designate of Mural Oncology.

Dr. Loew will be joined by members of the Mural Oncology team for a presentation followed by a question-and-answer session.

Alkermes expects to complete the separation of its oncology business into Mural Oncology plc in the fourth quarter of 2023, subject to customary conditions, including effectiveness of the Form 10 registration statement for Mural Oncology plc, a favorable opinion with respect to the tax-free nature of the separation, and final approval of Alkermes’ board of directors.

Investors are invited to listen to the live webcast, which can be accessed on the Investors section of Alkermes’ website at www.alkermes.com or by dialing the U.S. toll free number + 1 866 400 0049, confirmation code 1830332. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes’ website.

CanariaBio and Hikma announce the signing of distribution and license agreement for oregovomab in MENA Region

On October 10, 2023 CanariaBio Inc. and Hikma MENA FZE, part of Hikma Pharmaceuticals PLC (Hikma), reported the signing of distribution and license agreement for oregovomab in the Middle East and North Africa (MENA) region (Press release, CanariaBio, OCT 10, 2023, View Source [SID1234635726]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are thrilled to partner with Hikma, a company with a strong presence in the MENA region and a proven track record of successful collaborations," said Michael Na, CEO of CanariaBio.

Oregovomab is being tested in combination with carboplatin and paclitaxel for patients with advanced ovarian cancer in the phase 3 FLORA-5 trial. In Phase 2, the addition of oregovomab yielded a median progression-free survival of 41.8 months compared with 12.2 months with standard chemotherapy (HR, 0.46, P=0.0027). The hazard ratio of overall survival was 0.35.

About Oregovomab

Oregovomab is a murine monoclonal antibody direct to the tumor-associated antigen CA125 that stimulates a host cytotoxic immune response against tumor cells expressing CA 125, a biomarker commonly found in ovarian cancer (OC). In a randomized Phase II clinical trial, oregovomab demonstrated a significant improvement in progression-free and overall survival in advanced OC treatment when administered simultaneously with first-line chemotherapy. This promising schedule is currently investigated in a phase III trial.

Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA® (pembrolizumab)

On October 10, 2023 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, reported that the first patient of the Phase I part B clinical trial evaluating the combination of BT-001 and MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) has been dosed (Press release, Transgene, OCT 10, 2023, View Source [SID1234635723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase I Part B of the trial explores repeated intra-tumoral injections of BT-001 in combination with intravenous infusions of KEYTRUDA. Transgene and BioInvent plan to enroll a minimum of 12 patients with metastatic or advanced solid tumors, including melanoma. In accordance with our clinical trial and supply agreement, KEYTRUDA is being supplied by MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA). Trial endpoints include safety, evaluation of efficacy, and assessment of immune changes in the tumor microenvironment.

Transgene and BioInvent are co-developing BT-001, an oncolytic virus designed using Transgene’s Invir.IO platform encoding BioInvent’s differentiated anti-CTLA-4 antibody and human GM-CSF cytokine to elicit a strong and effective anti-tumoral response. The drug is currently being evaluated against solid tumors in a Phase I/IIa clinical trial as a single agent and in combination with the PD-1 checkpoint inhibitor KEYTRUDA.

The inclusion of the last patient in Part B of the study is expected in H1 2024.

Previously reported Phase I data confirmed the mechanism of action of BT-001 as a single agent and demonstrated first signs of anti-tumoral activity.

Dr. Martin Welschof, CEO of BioInvent and Dr. Alessandro Riva, Chairman and CEO of Transgene, added: "By combining BT-001 with pembrolizumab, we are building upon the promising data generated by BT-001 as a single agent. Targeting the PD1/PD-L1 pathway in addition to BT-001’s mechanism of action is expected to further stimulate and restore the patient’s immune system, which should result in improved antitumoral activity and patient outcome. We are thrilled to enter this new phase of the development of the novel oncolytic virus BT-001 and further demonstrate its potential in combination with a reference treatment."

KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About the trial

The ongoing Phase I/IIa (NCT: 04725331) study is a multicenter, open label, dose-escalation trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). Patient inclusions are ongoing in Europe (France, Belgium) and the trial has been authorized in the US.

This Phase I is divided into two parts. In part A, patients with metastatic/advanced tumors received single agent, intra-tumoral administrations of BT-001. Part B is exploring intra-tumoral injections of BT-001 in combination with KEYTRUDA. In this part, KEYTRUDA is being provided to the trial by MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).

The Phase IIa will evaluate the combination regimen in several patient cohorts with selected tumor types. These expansion cohorts will offer the possibility of exploring the activity of this approach to treat other malignancies not traditionally addressed with this type of treatment.

About BT-001

BT-001 is an oncolytic virus generated using Transgene’s Invir.IO platform and its patented large-capacity VVcopTK-RR- oncolytic virus, which has been engineered to encode both a Treg-depleting recombinant human anti-CTLA-4 antibody generated by BioInvent’s proprietary n-CoDeR/F.I.R.S.T platforms, and the human GM-CSF cytokine. By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response. Therefore, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA-4 antibody may be greatly improved.

BT-001 is being co-developed as part of a 50/50 collaboration on oncolytic viruses between Transgene and BioInvent. To know more on BT-001, watch our video here.

HiFiBiO Therapeutics Receives Approval from Chinese NMPA for IND Application for HFB200301, an Innovative Anti-Tumor Monoclonal Antibody

On October 9, 2023 HiFiBiO Therapeutics, a clinical stage global biotech company focusing on improving patient lives with single cell precision, reported that the Chinese National Medical Products Administration (NMPA) has approved the company’s Investigational New Drug (IND) application for HFB200301, a pioneering, first-in-class anti-TNFR2 agonistic monoclonal antibody (Press release, HiFiBiO Therapeutics, OCT 10, 2023, View Source [SID1234635720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

HFB200301 is currently undergoing Phase I clinical trial (NCT05238883) evaluation in the treatment of advanced solid tumors in the United States and Europe, both as a monotherapy and in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor. This trial is guided by HiFiBiO’s proprietary Drug Intelligence Science (DIS) platform, which utilizes patient data to optimize dosages, dosing regimens, indication selection, and biomarker strategies.

Liang Schweizer, PhD, Founder, Chairperson, and CEO of HiFiBiO Therapeutics, commented on this significant development, saying, "The approval of our HFB200301 IND by the NMPA represents yet another pivotal milestone for the program, confirming our strong commitment to developing safe and effective treatments for cancer patients globally."

"Incorporating Chinese patients into our study will provide invaluable insights into the therapeutic potential of HFB200301 across a diverse patient population, ultimately guiding our efforts to develop novel immuno-oncology treatments to patients with significant unmet medical needs," emphasized Robert Andtbacka, MD, CM, CMO of HiFiBiO Therapeutics.

Under the terms of the previously announced clinical supply agreement, Novartis will supply tislelizumab for use in combination with HFB200301, and HiFiBiO Therapeutics will maintain control of the HFB200301 program, including global R&D and commercial rights.

HFB200301

HFB200301 is a first-in-class anti-TNFR2 agonistic monoclonal antibody that binds potently and selectively to TNFR2, and induces the activation of CD4 T cells, CD8 T cells, and NK cells. HFB200301 demonstrates potent antitumor activity as a monotherapy and in combination with anti-PD-1 in animal tumor models. HiFiBiO is implementing a biomarker strategy, leveraging its DIS platform, to identify indications that may benefit the most from HFB200301 as a monotherapy or as a combination therapy.

Tislelizumab
Tislelizumab, an investigational humanized IgG4 anti-PD-1 monoclonal antibody, is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages. Pre-clinical studies have shown that binding to Fcγ receptors on macrophages can compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.

Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents Article published in BMCL

On October 9, 2023 Kaiyue Life reported the company and other institutions jointly published a paper titled "Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents" in the classic journal of medicinal chemistry, Bioorganic and Medicinal Chemistry Letters (BMCL) (Press release, KeYe Life Technologies, OCT 9, 2023, View Source;article_id=84 [SID1234644610]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Recently, a collaborative paper titled "Development of small molecule inhibitors targeting RNA helicase DHX33 as anti-cancer agents" co-authored by Kaiyue Life Sciences, the University of Macau, Southern University of Science and Technology, and Heya Pharmaceuticals was published online in BMCL, a long-established journal of medicinal chemistry.

The RNA helicase DHX33 has been identified as a key player in promoting cancer development. Genetic deletion of DHX33 significantly blocks tumorigenesis. Importantly, its helicase activity was found to be critical for exerting cellular functions. In this study, a helicase-based high-throughput screening (HTS) technique was used to discover DHX33 inhibitors from the Chembridge chemical library containing 15,000 small molecules. We discovered a lead compound containing a benzimidazole ring that showed some selectivity for DHX33. Further structural optimization led to the design and synthesis of a series of mimetic inhibitors. Considering the potential role of DHX33 in cancer development, we evaluated these compounds based on their cytotoxic activity against U251-MG cancer cells in vitro. Among them, compound IVa (KY386) was identified as a selective inhibitor of DHX33 helicase with strong anticancer activity and moderate metabolic stability. These results support the important role of DHX33 inhibitors in the development of novel anticancer drugs.